Medulloblastoma

After completion of all planned therapy, all patients should have a history and physical, brain magnetic resonance imaging (MRI), and full blood count every 3-4 months for 2 years, then every 6 months for 3 years and then as clinically indicated thereafter.[3]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric central nervous system cancers [internet publication]. https://www.nccn.org/guidelines/category_1 ​ Low- and average-risk patients should also have spine MRI and lumbar puncture for cerebrospinal fluid (CSF) cytology every 6 months for 2 years and then as clinically indicated.[3]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric central nervous system cancers [internet publication]. https://www.nccn.org/guidelines/category_1 ​ High-risk patients should have spine MRI every 3-4 months for 2 years, then annually for 3 years, and then as clinically indicated, and lumbar puncture for CSF cytology every 3-4 months for 2 years and then as clinically indicated.[3]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric central nervous system cancers [internet publication]. https://www.nccn.org/guidelines/category_1 All patients also need long-term monitoring by a 'cancer survivorship' clinic looking for late therapy-related toxicities as well as secondary malignancies related to the radiotherapy. Such follow-up studies include endocrine evaluation, hearing test, skin and ophthalmology examinations annually for 5 years, and neurocognitive testing at 1, 3 and 5 years after therapy.[3]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric central nervous system cancers [internet publication]. https://www.nccn.org/guidelines/category_1